Table 1.
Clinicopathological parameters and genotypes of PRRs in this study
| Clinicopathological parameters | Total cases (%) | TIM3 (R140L/rs1036199) | P2RX7 (E496A/rs3751143) | TLR1(S602I/rs5743618) | FPR1 (E346A/rs867228) | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| GG + GT | TT | p value | AA + AC | CC | p value | GG + GT | TT | p value | AA + AC | CC | p value | ||
| 130 (100%) | 21(16%) | 109 (84%) | 124(95%) | 6 (5%) | 23 (18%) | 107 (82%) | 55 (43%) | 73 (57%) | |||||
| Age | 0.103 | 0.404 | 0.163 | 0.056 | |||||||||
| < 65 | 86 (66%) | 17 (81%) | 69 (63%) | 83 (67%) | 3 (50%) | 18 (78%) | 68 64%) | 31 (56%) | 53 (73%) | ||||
| ≥ 65 | 44 (34%) | 4 (19%) | 40(37%) | 41 (33%) | 3 (50%) | 5 (22%) | 39 (36%) | 24 (44%) | 20 (27%) | ||||
| Sex | 0.045* | 0.381 | 0.105 | 0.986 | |||||||||
| Female | 43 (33%) | 11 (52%) | 32 (29%) | 40 (32%) | 3 (50%) | 11 (48%) | 32 (30%) | 18 (33%) | 24 (33%) | ||||
| Male | 87 (67%) | 10 (48%) | 77 (71%) | 84 (68%) | 3 (50%) | 12(52%) | 75 (70%) | 37 (67%) | 49 (67%) | ||||
| Histological grade | 0.619 | 0.357 | 0.895 | 0.643 | |||||||||
| Well | 6 | 1 (5%) | 5 (5%) | 6 (5%) | 6 (100%) | 1 (4%) | 5 (5%) | 1 (1.8%) | 4 (5%) | ||||
| Moderate | 100 | 18 (85%) | 82 (75%) | 94 (76%) | 0 (0%) | 19 (83%) | 81 (75%) | 42 (76%) | 57 (78%) | ||||
| Poor | 8 | 1 (5%) | 7 (6%) | 8 (6%) | 0 (0%) | 1 (4%) | 7 (7%) | 4 (7%) | 4 (5%) | ||||
| Unknown | 16 | 1 (5%) | 15 (14%) | 16 (13%) | 0 (0%) | 2 (9%) | 14 (13%) | 8 (15%) | 8 (11%) | ||||
| TMN stage (7th AJCC) | 0.147 | 0.129 | 0.133 | 0.033* | |||||||||
| I | 5 (4%) | 1 (1%) | 4 (4%) | 5 (24%) | 1 (17%) | 0 (00%) | 5 (5%) | 1 (2%) | 4 (5%) | ||||
| II | 50 (38%) | 10 (53%) | 40 (36%) | 33 (27%) | 3 (50%) | 10 (44%) | 40 (37%) | 21 (38%) | 28 (39%) | ||||
| III | 69 (53%) | 8 (42%) | 61 (55%) | 40 (36%) | 2 (33%) | 12 (52%) | 57 (53%) | 33 (60%) | 35 (48%) | ||||
| IV | 6 (5%) | 0 (0%) | 6 (5%) | 5 (4%) | 0 (0%) | 1 (4%) | 5 (5%) | 0 (0%) | 6 (8%) | ||||
| pN stage | 0.768 | 0.882 | 0.744 | 0.658 | |||||||||
| Negative | 83 (64%) | 14 (67%) | 69 (63%) | 79 (64%) | 4 (67%) | 14 (61%) | 69 (64%) | 36 (66%) | 45 (62%) | ||||
| Positive | 47 (36%) | 7 (33%) | 40 (37%) | 45 (36%) | 2 (33%) | 9 (39%) | 38 (36%) | 19 (34%) | 28 (38%) | ||||
| TRG | 0.157 | 0.204 | 0.178 | 0.093 | |||||||||
| 4 | 13 (10%) | 1 (5%) | 12 (11%) | 13 (10%) | 0 (0%) | 1 (4%) | 12 (11%) | 6 (11%) | 7 (10%) | ||||
| 3 | 71 (55%) | 11 (52%) | 60 (55%) | 68 (55%) | 3 (50%) | 13 (57%) | 58 (54%) | 36 (65%) | 34 (46%) | ||||
| 2 | 29 (22%) | 8 (38%) | 21 (19%) | 26 (21%) | 3 (50%) | 8 (35%) | 21 (20%) | 7 (13%) | 21 (29%) | ||||
| 1 | 17 (13%) | 1 (5%) | 16 (15%) | 17 (14%) | 0 (0%) | 1 (4%) | 15 (15%) | 6 (11%) | 11 (15%) | ||||
| Clinical response | 0.768 | 0.23 | 0.949 | 0.579 | |||||||||
| Complete response | 13 (10%) | 1 (5%) | 12 (11%) | 13 (11%) | 0 (0%) | 2 (9%) | 11 (10%) | 6 (11%) | 7 (10%) | ||||
| Partial response | 48 (37%) | 9 (43%) | 39 (36%) | 47 (38%) | 1 (17%) | 8 (34%) | 40 (37%) | 18 (33%) | 28 (38%) | ||||
| Stable disease | 61 (47%) | 10 (47%) | 51 (47%) | 56 (45%) | 5 (83%) | 11 (48%) | 50 (47%) | 29 (52%) | 32 (44%) | ||||
| Progression disease | 8 (6%) | 1 (5%) | 7 (6%) | 8 (6%) | 0 (0%) | 2 (9%) | 6 (6%) | 2 (4%) | 6 (8%) | ||||
| Concurrent chemotherapy | 0.816 | 0.402 | 0.589 | 0.024* | |||||||||
| Capecitabine | 57 (44%) | 8 (38%) | 49 (45%) | 53 (43%) | 4 (66%) | 8 (35%) | 49 (46%) | 23 (42%) | 32 (44%) | ||||
| UFT | 51 (39%) | 10 (48%) | 41 (38%) | 50 (40%) | 1 (17%) | 11 (48%) | 40 (38%) | 25 (46%) | 26 (36%) | ||||
| 5-FU | 12 (9%) | 2 (10%) | 10 (9%) | 11 (9%) | 1 (17%) | 3 (13%) | 9 (8%) | 7 (13%) | 5 (7%) | ||||
| Others | 10 (8%) | 1 (5%) | 9 (8%) | 10 (8%) | 0 (0%) | 1 (4%) | 9 (8%) | 0 (0%) | 10 (14%) | ||||
| Lymphovascular invasion (LVI) | 0.565 | 0.248 | 0.792 | 0.162 | |||||||||
| Absent | 99 (76%) | 17 (81%) | 82 (75%) | 95 (77%) | 4 (67%) | 18 (78%) | 81 (76%) | 45 (82%) | 52 (71%) | ||||
| Present | 31 (24%) | 4 (19%) | 27 (25%) | 29 (23%) | 2 (33%) | 5 (220%) | 26 (24%) | 10 (18%) | 21 (29%) | ||||
| Perineural invasion (PNI) | 0.853 | 0.723 | 0.679 | 0.106 | |||||||||
| Absent | 95 (73%) | 15 (71%) | 80 (73%) | 91 (73%) | 4 (67%) | 16 (70%) | 79 (74%) | 44 (80%) | 49 (67%) | ||||
| Present | 35 (27%) | 6 (29%) | 29 (27%) | 33 (27%) | 2 (33%) | 7 (30%) | 28 (26%) | 11 (20%) | 24 (33%) | ||||
| Distance metastasis | 0.358 | 0.645 | 0.197 | 0.093 | |||||||||
| No | 73 (57%) | 14 (67%) | 61 (56%) | 71 (57%) | 4 (67%) | 16(70%) | 59 (55%) | 36 (65%) | 37 (51%) | ||||
| Yes | 55 (43%) | 7 (33%) | 48 (44%) | 53 (43%) | 2 (33%) | 7 (30%) | 48 (45%) | 19 (35%) | 36 (49%) | ||||
| pre-CCRT CD8+ TILs | 0.267 | 0.293 | 0.397 | 0.039* | |||||||||
| Low | 86 (70%) | 16 (80%) | 70 (68%) | 83 (71%) | 3 (50%) | 17 (77%) | 69 (68%) | 30 (60%) | 55 (77%) | ||||
| High | 37 (30%) | 4 (20%) | 33 (32%) | 34 (29%) | 3 (50%) | 5 (23%) | 32 (32%) | 20 (40%) | 16 (23%) | ||||
| NA | 7 | 1 | 6 | 7 | 0 | 7 | 6 | 5 | 2 | ||||
pN stage: positive (Stage 1a + 1b + 2) Versus negative (Stage 0); CD8+ TILs: high (grade 2 + 3) Versus low (grade 0 + 1); Chi-squared test was used. Fisher's exact test was used when > 25% of the cells had expected counts < 5. NA: not available. The contrast test did not include the “NA” group